Published in Int Rev Immunol on August 01, 2012
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol Res (2014) 0.97
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Res (2015) 0.79
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 12.07
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science (1993) 5.04
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 4.77
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell (1993) 4.30
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood (2010) 4.28
Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science (1995) 3.76
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 3.72
Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A (1986) 3.68
Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science (1991) 3.56
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63
The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol (1987) 2.55
Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol (1992) 2.54
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol (2003) 2.50
B cells inhibit induction of T cell-dependent tumor immunity. Nat Med (1998) 2.50
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res (2003) 2.40
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
The 'short' history of regulatory B cells. Trends Immunol (2007) 2.38
Immunology. Licence to kill. Nature (1998) 2.34
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol (2001) 2.12
Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res (2011) 2.11
Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol (2009) 1.87
Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res (2007) 1.75
SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol (2004) 1.75
Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol (1992) 1.72
Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood (2008) 1.64
RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood (2003) 1.62
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol (1998) 1.50
CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J Immunol (1996) 1.47
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol (2001) 1.33
Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med (2005) 1.31
TRAF proteins in CD40 signaling. Adv Exp Med Biol (2007) 1.27
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol (2006) 1.18
CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood (2005) 1.17
Runaway domain swapping in amyloid-like fibrils of T7 endonuclease I. Proc Natl Acad Sci U S A (2006) 1.16
Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem (1999) 1.12
Maturation and function of human dendritic cells are regulated by B lymphocytes. Blood (2011) 1.07
CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol (2008) 1.05
Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol (2004) 1.01
Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry (1995) 1.01
CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology (2007) 0.99
Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res (1997) 0.98
Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol (2006) 0.95
Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther (2007) 0.95
Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. Cell Immunol (1993) 0.94
Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol (1998) 0.93
CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS One (2011) 0.88
Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther (1997) 0.87
Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology (2008) 0.87
Activated T cells induce rapid CD83 expression on B cells by engagement of CD40. Immunol Lett (2011) 0.86
B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state. Int Immunol (1998) 0.85
A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. Vaccine (2008) 0.84
Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy. Virol J (2010) 0.84
Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Blood (2011) 0.84
CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells. PLoS One (2012) 0.84
Detailed comparison of two molecular models of the human CD40 ligand with an x-ray structure and critical assessment of model-based mutagenesis and residue mapping studies. J Biol Chem (1998) 0.82
CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome. Clin Immunol (2012) 0.81
Biophysical characterization of a soluble CD40 ligand (CD154) coiled-coil trimer: evidence of a reversible acid-denatured molten globule. Arch Biochem Biophys (2001) 0.80
Immunology. The adjuvant effects of antibodies. Science (2011) 0.77
Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J Immunother (2009) 0.76
Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J Leukoc Biol (2006) 1.10
Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine (2011) 0.98
Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes. Vaccine (2011) 0.96
The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine (2009) 0.86
A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. J Infect Dis (2013) 0.85
Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunol (2009) 0.84
EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine. J Leukoc Biol (2011) 0.78
Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines. Retrovirology (2011) 0.77
Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics. Immunol Res (2013) 0.76